Two National Guard members shot near White House
BURLINGTON, N.C. - Labcorp (NYSE:LH) announced Monday the appointment of Victor Bulto to its Board of Directors, effective December 1, 2025. The $22 billion market cap laboratory services provider, which boasts a "GREAT" financial health score according to InvestingPro, has seen its shares rise nearly 17% year-to-date.
Bulto, who currently serves as President of Novartis’ U.S. operations, brings 25 years of healthcare industry experience to the laboratory services provider. At Novartis, he oversees a $20+ billion business spanning oncology, immunology, neuroscience, and cardiovascular-renal-metabolic therapeutic areas.
According to a company press release, Bulto has expertise in transformation and implementing technology and automation to streamline operations and build future-ready business models.
"Victor’s appointment to our Board underscores Labcorp’s focus on long-term growth through innovation and global healthcare leadership," said Adam Schechter, Chairman and Chief Executive Officer of Labcorp.
Bulto stated, "I deeply believe in Labcorp’s mission and am honored to join the Board at a time of industry growth and medical advancement, particularly in the field of precision medicine."
Labcorp provides laboratory services to doctors, hospitals, pharmaceutical companies, and researchers across approximately 100 countries. The company employs nearly 70,000 people worldwide and supported more than 75% of new drugs and therapeutic products approved by the FDA in 2024. The prominent healthcare provider reported $13.8 billion in revenue over the last twelve months with 8.3% growth, while maintaining a perfect Piotroski Score of 9, indicating exceptional financial strength. InvestingPro analysis reveals 8+ additional insights about Labcorp’s performance in its comprehensive Pro Research Report, available for subscribers seeking deeper investment intelligence.
In other recent news, Labcorp Holdings reported strong financial results for the third quarter of 2025. The company achieved an adjusted earnings per share (EPS) of $4.18, slightly exceeding the forecasted $4.13, which represents a positive surprise of 1.21%. Labcorp’s revenue for the quarter reached $3.6 billion, meeting analysts’ projections. Despite these favorable earnings and revenue results, the stock saw a decline due to broader market concerns. Leerink Partners has maintained an Outperform rating on Labcorp stock, with a price target of $342.00. The firm views the recent dip in stock price as a buying opportunity, describing Labcorp as a "durable compounder" with improving growth drivers. These developments reflect a mixed sentiment among investors, balancing strong earnings performance with market apprehensions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.